MedTrace Logo

Prediction of Exacerbations and Management of COPD Patients With SAH Based on Millimeter Wave Radar Monitoring

NCT05019911 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 922

Last updated 2021-08-25

No results posted yet for this study

Summary

Millimeter wave radar will be used to conduct non-contact monitoring continuously for patients' vital signs (eg. respiratory rate, heart rate, and chest/abdominal movement). The monitoring information will be transmitted to the central system through network and displayed in real time. Comparison with polysomnography will be done to examine the consistency between the two devices in diagnosing sleep breathing disorders. The predictive model of acute exacerbations of COPD will be established with the baseline indicators considered.

Conditions

  • COPD
  • Sleep Apnea Hypopnea Syndrome
  • Acute Exacerbation of COPD

Interventions

DEVICE

Polysomnography

In the cross-sectional part, the group of patients with COPD alone and the group of patients with COPD combined with sleep apnea hypopnea syndrome will be monitored by traditional sleep monitoring equipment (polysomnography) for vital signs in order to diagnose COPD combined with sleep apnea hypopnea syndrome.

DEVICE

Millimeter wave radar equipment

In the cross-sectional part, the group of patients with COPD alone and the group of patients with COPD combined with sleep apnea hypopnea syndrome will be monitored by millimeter wave radar equipment for vital signs in order to diagnose COPD combined with sleep apnea hypopnea syndrome. In the cohort part, both groups of patients will be continuously monitored by millimeter wave radar equipment for vital signs for months in order to establish a model to predict acute exacerbations of COPD combined with sleep apnea hypopnea syndrome.

Sponsors & Collaborators

  • Tsinghua University

    collaborator OTHER

  • Peking University Third Hospital

    lead OTHER

Principal Investigators

  • Yahong Chen · Peking University Third Hospital

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-31
Primary Completion
2021-11-30
Completion
2022-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05019911 on ClinicalTrials.gov